A study found that sentinel lymph node biopsy rarely missed remaining cancer in patients with locally advanced breast cancer whose lymph nodes responded to chemotherapy before surgery.
Alternating two long-used bladder treatments cleared cancer in 24 of 25 patients whose disease had returned after BCG, an early study found. A larger trial comparing the approach with BCG alone is now enrolling.
The FDA has cleared TumorSight Risk, software that uses a patient's existing breast MRI, pathology and clinical information to estimate the chance that early HR-positive, HER2-negative breast cancer will come back within five and 10 years.
Twenty-four years after breast cancer, one survivor reflects on mammogram anxiety, the relief of clear results and the gratitude of living beyond cancer.
In a randomized trial of nearly 100,000 women in Germany, 3D mammography found a larger share of breast cancers at the screening visit, but its 24% lower rate of cancers found between screenings was not statistically significant.